Ophthalmology Management

12/23/2025

🚨 PATCH AMD milestone! 👁️‍🗨️

Regenerative Patch Technologies has treated the first 2 patients in a phase 2b trial testing an allogeneic bioengineered RPE implant for dry AMD with GA.

More details 👉 🔗 https://ow.ly/joV450XM9gl

12/22/2025

👁️ Presbyopia drops are revolutionizing care for aging eyes.

More than just a quick fix, they act as a strategic entry point for lifelong eye health.

Dr. Mitchell A. Jackson and Dr. Melissa Bollinger dive into how presbyopia drops offer flexibility, discretion, and customization - helping patients with age-related vision changes and laying the foundation for future treatments. 🌱

Read more on how these drops can transform your patients’ care in Ophthalmology Management 🔗 https://ow.ly/74aW50XKaBp

Presbyopia drops are more than just a new tool—they’re a strategic entry point into the lifelong care pathway for patients with presbyopia.

12/19/2025

👁️‍🗨️ Corneal scarring can steal vision - but transplant isn’t always the answer.

In this article, Sumitra S. Khandelwal, MD walks through a stepwise approach to medical + surgical management - from first-line medical therapy and scleral lenses to depth-based surgical options (superficial keratectomy, PTK, ALK/DALK), with PKP reserved for severe cases. 🩺

Read: Medical and Surgical Management of Corneal Scarring ⬇️
🔗 https://ow.ly/fYlh50XJIFw

12/18/2025

👁️ Laser “top-up” may help keep glaucoma pressure down 👇

A new independent, real-world study reported that MicroPulse transscleral laser retreatment can safely and effectively further lower eye pressure in people with moderate to advanced glaucoma.

At 3 months after retreatment, patients saw meaningful pressure reductions (~25–35%), including those who didn’t respond strongly to the first procedure.

👉 Read more: https://ow.ly/mv4H50XKpOM

12/17/2025

🟢 FDA greenlights a new generic combo eye drop

Alembic Pharmaceuticals Limited has received FDA approval for a generic version of Zylet - an eye drop that combines a steroid to reduce inflammation and an antibiotic to treat/prevent bacterial infection.

The company says it qualifies for 180 days of “first-generic” exclusivity when it’s commercialized, meaning it could be one of the only generic options available for a period after launch.

👉 Read more about what the approval means for access and availability: https://ow.ly/lw9M50XKpvo

12/15/2025

👓 Presbyopia is unavoidable - but patients want solutions earlier than ever.

In this interview, Kathryn M. Hatch, MD breaks down today’s surgical + nonsurgical options (RLE, advanced IOLs, monovision, drops) and why patient selection & expectation-setting matter as much as the tech.

Read: “Trying to Avoid the Unavoidable” to read the full interview ⬇️
https://ow.ly/25EC50XJI9M

Presbyopia is an unavoidable condition of the aging eye, making it a central concern for general ophthalmologists and refractive surgeons alike.

12/12/2025

👁️ Dry eye drug update

Following a positive FDA pre-NDA meeting for AZR-MD-001, Azura Ophthalmics says it plans NDA submission with completed efficacy studies.

👉 Read the full update: https://ow.ly/LMQg50XImG2

12/10/2025

Presbyopia is often the first “wait, what’s happening to my vision?” moment and it can be the start of a long-term care relationship. 👁️💧

In this video interview, Mitchell Jackson, MD, and Melissa Bollinger, OD (Jacksoneye, Lake Villa, Illinois) explain how they introduce presbyopia drops to emmetropic patients noticing “The Big A.G.E.” and which patient groups tend to love the option most (first-time readers, post-LASIK, contact lens wearers, and even some post-cataract patients).

They also cover practical must-dos like staff education, realistic expectations, and why a proper dilated retinal exam matters.

Watch the full video: https://ow.ly/vS4E50XFKfy

Mitchell Jackson, MD, and Melissa Bollinger, OD, of Jacksoneye in Lake Vila, Illinois discuss how offering presbyopia drops to emmetropic patients experiencing vision changes due to "The Big A.G.E." c...

12/09/2025

🚨 Cornea update: EyeYon Medical has FDA IDE approval to launch a US clinical study of EndoArt, a synthetic endothelial layer for chronic corneal edema.

The study will be led by Professor Francis Mah, MD (Scripps Clinic) and include 10+ leading US cornea surgeons nationwide.

Read the full update in Ophthalmology Management: https://ow.ly/LW9E50XG8pX

12/08/2025

Could compounded imiquimod be a new option for challenging ocular surface tumors? 👁️🧴

A small Northwestern case series in JAMA Ophthalmology reports 80% complete histologic response in diffuse conjunctival MIS/OSSN, but all patients had ocular surface or eyelid side effects that resolved with breaks or after treatment.

Read more: https://ow.ly/nHUA50XCCFI

12/05/2025

Can a 5-year visit help predict long-term outcomes in childhood glaucoma? 👁️🧒

A multicenter CGRN study found key early measures, especially at year 5, were linked to long-term visual acuity and IOP, and calls for better severity staging to guide care.

Read more: https://ow.ly/4JfO50XCCwq

12/04/2025

Precise Bio has achieved the world’s first successful 3D-bio-printed corneal implant.

A legally blind patient in Israel received the PB-001 implant, marking a major step toward lab-grown, donor-free corneal tissue. Early trial results expected in 2026. 👁️🧬

Read more: https://ow.ly/u6a850XybzP